


Human Chandipura (CHPV) IgM ELISA

Domain: Diagnostic Assay/Kit

About Technology: CHPV causes high fatality in children; early detection via IgM antibodies is vital. This is the first indigenous Human CHPV IgM ELISA kit. The kit supports surveillance to identify high-risk regions

Intended Use: Qualitative detection of IgM antibodies in serum or CSF from patients with symptoms suggestive of CHPV encephalitis, Suitable for laboratory diagnosis of CHPV at sentinel hospitals and primary health centers.



Advantages:

- First indigenous Human CHPV IgM ELISA kit
- Sensitive, rapid and user friendly
- Safe for BSL-2 labs
- Cost effective

Development Status: Third party validation complete

Technology Transfer Status: Transferred to companies on Non-Exclusive basis (Some licensees have already received Manufacturing License from CDSCO)

Institute(s): ICMR-National Institute of Virology (NIV)

Inventor(s): Dr. GN Sapkal, Dr. VP Bondre

For Licensing Opportunities contact: patentmitra.hq@icmr.gov.in